Advagene Biopharma Co (ROCO:6709) Debt-to-Equity : 0.02 (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Advagene Biopharma Co Debt-to-Equity?

Advagene Biopharma Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was NT$1.63 Mil. Advagene Biopharma Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was NT$0.00 Mil. Advagene Biopharma Co's Total Stockholders Equity for the quarter that ended in Jun. 2023 was NT$85.13 Mil. Advagene Biopharma Co's debt to equity for the quarter that ended in Jun. 2023 was 0.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Advagene Biopharma Co's Debt-to-Equity or its related term are showing as below:

ROCO:6709' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.02
Current: 0.01

During the past 8 years, the highest Debt-to-Equity Ratio of Advagene Biopharma Co was 0.02. The lowest was 0.00. And the median was 0.01.

ROCO:6709's Debt-to-Equity is ranked better than
99.91% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs ROCO:6709: 0.01

Advagene Biopharma Co Debt-to-Equity Historical Data

The historical data trend for Advagene Biopharma Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advagene Biopharma Co Debt-to-Equity Chart

Advagene Biopharma Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.02

0.01

Advagene Biopharma Co Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial										0.02	0.02	0.02	0.02	0.01

Competitive Comparison of Advagene Biopharma Co's Debt-to-Equity

For the Biotechnology subindustry, Advagene Biopharma Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Advagene Biopharma Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Advagene Biopharma Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Advagene Biopharma Co's Debt-to-Equity falls into.

Advagene Biopharma Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Advagene Biopharma Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.87	+	0)	/	139.962
	=	0.01

Advagene Biopharma Co's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.626	+	0)	/	85.133
	=	0.02

Advagene Biopharma Co (ROCO:6709) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Advagene Biopharma Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Advagene Biopharma Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Advagene Biopharma Co (ROCO:6709) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advagene Biopharma Co Ltd (ROCO:6709) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Sector 1, Neihu Road, 6 Floor, No.308, Neihu District, Taipei, TWN, 114

Website

http://www.advagene.com.tw

Advagene Biopharma Co Ltd is a Taiwan based immune-modulatory platform-based drug developer. The company has completed technology transfer with DCB for detoxified LT Adjuvant Technology Platform. Its product development includes nasal spray influenza vaccine (LT-Flu), allergy vaccines (LT-Allergy), and other vaccines.

Advagene Biopharma Co (ROCO:6709) Headlines

No Headlines